TYRA

Tyra Biosciences, Inc.

Price Chart

Latest Quote

$29.07

+0.86 (+3.05%)

Current Price

Previous Close	$28.21
Open	$28.83
Day High	$29.57
Day Low	$28.48
Volume	729,062

Fetched: 2026-06-18T04:14:48

Stock Information

Shares Outstanding	59.47M
Total Debt	$5.70M
Cash Equivalents	$383.47M
Net Income	$-131.10M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$1.73B
EPS (TTM)	$-2.18
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$1.30B
Income	$-131.10M
Book/sh	$4.83
Cash/sh	$6.45
Employees	87

Financial Ratios

Quick Ratio	20.05
Current Ratio	20.49
Debt/Eq	1.47

Returns & Margins

ROA	-23.64%
ROE	-36.87%

Ownership

Insider Ownership	2.86%
Institutional Ownership	111.51%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-10.29
P/B	6.02

Analyst Data

Recommendation	strong_buy
Target Price	$51.60

Technical Indicators

SMA20	$29.49
SMA50	$33.02
SMA200	$26.10
RSI	36.46
ATR	1.9980

Shares Float	30.88M
Short Float	28.85%
Short Ratio	12.54
Volatility	0.75
Rel Volume	0.83

Performance History

Week	+14.36%
Month	-18.48%
Quarter	-23.60%
6 Months	+31.42%
YTD	+8.51%
Year	+184.44%
3 Years	+87.91%
10 Years	+11.81%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-17	$29.07	744,000
2026-06-16	$28.21	633,600
2026-06-15	$28.55	987,100
2026-06-12	$26.99	1,013,800
2026-06-11	$25.57	1,298,300
2026-06-10	$25.42	648,800
2026-06-09	$25.94	1,424,000
2026-06-08	$26.75	1,198,500
2026-06-05	$26.64	1,488,000
2026-06-04	$27.18	1,322,700
2026-06-03	$28.69	770,300
2026-06-02	$28.66	716,800
2026-06-01	$30.39	1,077,300
2026-05-29	$33.41	1,077,900
2026-05-28	$32.68	494,800
2026-05-27	$33.17	375,700
2026-05-26	$33.59	568,100
2026-05-22	$32.47	312,000
2026-05-21	$33.02	609,700
2026-05-20	$33.40	1,149,300
2026-05-19	$33.78	1,110,100
2026-05-18	$35.66	757,300

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in clinical trial for intrahepatic cholangiocarcinoma; and TYRA-430 for the treatment of hepatocellular carcinoma. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.

📰 Latest News

Is Tyra Biosciences (TYRA) Too Reliant On Dabogratinib Amid Renewed SURF-302 Skepticism?

Simply Wall St. • 2026-06-12T01:16:01Z

Tyra Biosciences' Weak Investor Sentiment Reflects Macro Pressures, Renewed SURF-302 Concerns, BofA Says

MT Newswires • 2026-06-10T14:57:06Z

Wolfe Research Initiates Peer Perform rating on Tyra Biosciences, Inc. (TYRA)

Insider Monkey • 2026-06-01T08:03:21Z

Tyra Biosciences Stock Has Soared 280% in a Year. One Fund Just Disclosed Buying More Shares

Motley Fool • 2026-05-17T19:01:48Z

Assessing Tyra Biosciences (TYRA) Valuation After Strong One Year Share Price Momentum

Simply Wall St. • 2026-05-14T13:20:22Z

Guggenheim Starts Tyra Biosciences, Inc. (TYRA) at Buy on Strength of Lead Drug Dabogratinib

Insider Monkey • 2026-04-24T13:42:55Z

A Look At Tyra Biosciences (TYRA) Valuation After $126 Million Stock Sale And Late Stage Trial Progress

Simply Wall St. • 2026-04-04T10:09:26Z

This Biotech Stock Has Surged 250% in a Year as One Investor Discloses $10 Million New Position

Motley Fool • 2026-03-20T16:21:06Z

Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet.

Motley Fool • 2026-03-19T19:23:04Z

Biotech Stock Jumps 288% Amid Massive Raise as One Early Backer Reports $14 Million Exit

Motley Fool • 2026-03-18T18:08:40Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$0	$0	$0	$0
Operating Revenue	$0	$0	$0	$0
Expenses
Total Expenses	$132,762,000	$104,177,000	$79,945,000	$58,927,000
Net Non Operating Interest Income Expense	$12,815,000	$17,696,000	$10,811,000	$3,652,000
Operating Expense	$132,762,000	$104,177,000	$79,945,000	$58,927,000
General And Administrative Expense	$29,834,000	$24,100,000	$17,427,000	$15,919,000
Other Income Expense	-	-	$-39,000	$-50,000
Other Non Operating Income Expenses	-	-	$-39,000	$-50,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Net Interest Income	$12,815,000	$17,696,000	$10,811,000	$3,652,000
Interest Income	$12,815,000	$17,696,000	$10,811,000	$3,652,000
Normalized Income	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Net Income From Continuing And Discontinued Operation	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Total Operating Income As Reported	$-132,762,000	$-104,177,000	$-79,945,000	$-58,927,000
Net Income Common Stockholders	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Net Income	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Net Income Including Noncontrolling Interests	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Net Income Continuous Operations	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Pretax Income	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Interest Income Non Operating	$12,815,000	$17,696,000	$10,811,000	$3,652,000
Operating Income	$-132,762,000	$-104,177,000	$-79,945,000	$-58,927,000
Per Share
Diluted EPS	$-2.01	$-1.51	$-1.62	$-1.32
Basic EPS	$-2.01	$-1.51	$-1.62	$-1.32
Other
Tax Effect Of Unusual Items	$0	$0	$0	$0
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-132,216,000	$-103,658,000	$-79,588,000	$-58,631,000
Reconciled Depreciation	$546,000	$519,000	$357,000	$296,000
EBITDA (Bullshit earnings)	$-132,216,000	$-103,658,000	$-79,588,000	$-58,631,000
EBIT	$-132,762,000	$-104,177,000	$-79,945,000	$-58,927,000
Diluted Average Shares	$59,602,328	$57,217,746	$42,704,876	$41,883,904
Basic Average Shares	$59,602,328	$57,217,746	$42,704,876	$41,883,904
Diluted NI Availto Com Stockholders	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Research And Development	$102,928,000	$80,077,000	$62,518,000	$43,008,000
Selling General And Administration	$29,834,000	$24,100,000	$17,427,000	$15,919,000
Other Gand A	$29,834,000	$24,100,000	$17,427,000	$15,919,000

Fetched: 2026-06-15

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$259,177,000	$343,151,000	$204,262,000	$257,829,000
Total Assets	$282,609,000	$363,558,000	$225,857,000	$266,181,000
Total Non Current Assets	$17,159,000	$16,095,000	$14,186,000	$8,893,000
Other Non Current Assets	$10,272,000	$8,376,000	$6,032,000	$5,350,000
Current Assets	$265,450,000	$347,463,000	$211,671,000	$257,288,000
Other Current Assets	$9,447,000	$6,022,000	$8,202,000	$6,075,000
Cash Cash Equivalents And Short Term Investments	$256,003,000	$341,441,000	$203,469,000	$251,213,000
Cash And Cash Equivalents	$77,387,000	$91,966,000	$58,006,000	$251,213,000
Prepaid Assets	-	-	-	-
Debt
Total Debt	$5,810,000	$6,222,000	$6,496,000	$2,622,000
Long Term Debt And Capital Lease Obligation	$5,338,000	$5,810,000	$6,216,000	$2,482,000
Current Debt And Capital Lease Obligation	$472,000	$412,000	$280,000	$140,000
Liabilities
Total Liabilities Net Minority Interest	$23,432,000	$20,407,000	$21,595,000	$8,352,000
Total Non Current Liabilities Net Minority Interest	$5,338,000	$5,813,000	$6,262,000	$2,651,000
Current Liabilities	$18,094,000	$14,594,000	$15,333,000	$5,701,000
Payables And Accrued Expenses	$17,622,000	$14,182,000	$15,053,000	$5,561,000
Payables	$1,178,000	$590,000	$4,662,000	$1,145,000
Accounts Payable	$1,178,000	$590,000	$4,662,000	$1,145,000
Other Non Current Liabilities	-	$3,000	$46,000	$169,000
Equity
Common Stock Equity	$259,172,000	$343,146,000	$204,262,000	$257,829,000
Preferred Stock Equity	$5,000	$5,000	-	-
Total Equity Gross Minority Interest	$259,177,000	$343,151,000	$204,262,000	$257,829,000
Stockholders Equity	$259,177,000	$343,151,000	$204,262,000	$257,829,000
Gains Losses Not Affecting Retained Earnings	$393,000	$770,000	$381,000	$0
Other Equity Adjustments	$393,000	$770,000	$381,000	-
Retained Earnings	$-371,258,000	$-251,311,000	$-164,830,000	$-95,696,000
Preferred Securities Outside Stock Equity	-	-	-	-
Other
Ordinary Shares Number	$53,706,357	$50,749,945	$43,024,634	$42,353,550
Share Issued	$53,706,357	$50,749,945	$43,024,634	$42,353,550
Tangible Book Value	$259,172,000	$343,146,000	$204,262,000	$257,829,000
Invested Capital	$259,172,000	$343,146,000	$204,262,000	$257,829,000
Working Capital	$247,356,000	$332,869,000	$196,338,000	$251,587,000
Capital Lease Obligations	$5,810,000	$6,222,000	$6,496,000	$2,622,000
Total Capitalization	$259,177,000	$343,151,000	$204,262,000	$257,829,000
Additional Paid In Capital	$630,037,000	$593,687,000	$368,707,000	$353,521,000
Capital Stock	$5,000	$5,000	$4,000	$4,000
Common Stock	$0	$0	$4,000	$4,000
Preferred Stock	$5,000	$5,000	$0	$0
Long Term Capital Lease Obligation	$5,338,000	$5,810,000	$6,216,000	$2,482,000
Current Capital Lease Obligation	$472,000	$412,000	$280,000	$140,000
Current Accrued Expenses	$16,444,000	$13,592,000	$10,391,000	$4,416,000
Net PPE	$6,887,000	$7,719,000	$8,154,000	$3,543,000
Gross PPE	$6,887,000	$7,719,000	$8,961,000	$4,004,000
Other Properties	$6,887,000	$7,719,000	$1,443,000	$1,119,000
Other Short Term Investments	$178,616,000	$249,475,000	$145,463,000	$0
Accumulated Depreciation	-	$-1,281,000	$-807,000	$-461,000
Leases	-	$469,000	$402,000	$156,000
Machinery Furniture Equipment	-	$588,000	$590,000	$263,000
Buildings And Improvements	-	$6,068,000	$6,526,000	$2,466,000
Properties	-	$0	$0	$0
Treasury Shares Number	-	-	-	-
Pensionand Other Post Retirement Benefit Plans Current	-	-	-	-

Fetched: 2026-06-15

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-95,283,000	$-70,438,000	$-50,909,000	$-50,844,000
Operating Activities
Operating Cash Flow	$-95,142,000	$-69,774,000	$-50,139,000	$-50,285,000
Cash Flow From Continuing Operating Activities	$-95,142,000	$-69,774,000	$-50,139,000	$-50,285,000
Operating Gains Losses	-	-	$4,000	$3,000
Investing Activities
Capital Expenditure	$-141,000	$-664,000	$-770,000	$-559,000
Investing Cash Flow	$72,463,000	$-98,403,000	$-144,605,000	$-559,000
Cash Flow From Continuing Investing Activities	$72,463,000	$-98,403,000	$-144,605,000	$-559,000
Financing Activities
Repurchase Of Capital Stock	$0	$-420,000	$0	-
Issuance Of Capital Stock	$0	$200,000,000	$0	$0
Financing Cash Flow	$8,100,000	$202,137,000	$1,537,000	$632,000
Cash Flow From Continuing Financing Activities	$8,100,000	$202,137,000	$1,537,000	$632,000
Net Common Stock Issuance	$0	$199,580,000	$0	$0
Common Stock Issuance	$0	$200,000,000	$0	$0
Net Preferred Stock Issuance	-	-	-	$0
Preferred Stock Issuance	-	-	-	$0
Net Other Financing Charges	-	-	-	-
Other
End Cash Position	$78,387,000	$92,966,000	$59,006,000	$252,213,000
Beginning Cash Position	$92,966,000	$59,006,000	$252,213,000	$302,425,000
Changes In Cash	$-14,579,000	$33,960,000	$-193,207,000	$-50,212,000
Proceeds From Stock Option Exercised	$8,100,000	$2,557,000	$1,537,000	$632,000
Common Stock Payments	$0	$-420,000	$0	-
Net Investment Purchase And Sale	$72,604,000	$-97,739,000	$-143,835,000	$0
Sale Of Investment	$173,858,000	$165,885,000	$0	-
Purchase Of Investment	$-101,254,000	$-263,624,000	$-143,835,000	$0
Net PPE Purchase And Sale	$-141,000	$-664,000	$-770,000	$-559,000
Purchase Of PPE	$-141,000	$-664,000	$-770,000	$-559,000
Change In Working Capital	$-1,628,000	$-729,000	$6,360,000	$-5,847,000
Change In Other Working Capital	$83,000	$184,000	$-186,000	$34,000
Change In Payables And Accrued Expense	$3,369,000	$-744,000	$9,369,000	$2,357,000
Change In Prepaid Assets	$-5,080,000	$-169,000	$-2,823,000	$-8,238,000
Stock Based Compensation	$28,006,000	$22,801,000	$13,525,000	$10,588,000
Amortization Of Securities	$-2,119,000	$-5,884,000	$-1,247,000	$0
Depreciation Amortization Depletion	$546,000	$519,000	$357,000	$296,000
Depreciation And Amortization	$546,000	$519,000	$357,000	$296,000
Depreciation	$546,000	$519,000	$357,000	-
Net Income From Continuing Operations	$-119,947,000	$-86,481,000	$-69,134,000	$-55,325,000
Gain Loss On Sale Of PPE	-	-	$4,000	$3,000
Repayment Of Debt	-	-	-	$0
Net Issuance Payments Of Debt	-	-	-	$0
Net Long Term Debt Issuance	-	-	-	$0
Long Term Debt Payments	-	-	-	$0
Sale Of PPE	-	-	-	$0
Change In Payable	-	-	-	$2,357,000
Change In Account Payable	-	-	-	$2,357,000
Interest Paid Supplemental Data	-	-	-	-

Fetched: 2026-06-15